https://scholars.lib.ntu.edu.tw/handle/123456789/484086
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | CHIH-HORNG WU | en_US |
dc.contributor.author | LI-CHUN LU | en_US |
dc.contributor.author | Chan S.-Y. | en_US |
dc.contributor.author | Ma Y.-Y. | en_US |
dc.contributor.author | Yen F.-C. | en_US |
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.creator | Yu-Yun Shao;Wu C.-H.;Lu L.-C.;Chan S.-Y.;Ma Y.-Y.;Yen F.-C.;Hsu C.-H.;Cheng A.-L. | - |
dc.date.accessioned | 2020-04-10T12:16:06Z | - |
dc.date.available | 2020-04-10T12:16:06Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0168-8278 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84892538394&doi=10.1016%2fj.jhep.2013.08.027&partnerID=40&md5=5d2a2c362c76d8d4ba663e1f8bca9368 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484086 | - |
dc.description.abstract | Background & Aims No approved therapy is available for patients with advanced hepatocellular carcinoma (HCC) who fail first-line therapy. The prognosis of these patients, especially those eligible for clinical trials of second-line therapy, is unclear. Methods All patients who participated in clinical trials of first-line systemic therapy for metastatic or locally advanced HCC in a referral center of Taiwan between 2005 and 2011 were included. Their clinicopathologic characteristics, when the first-line treatment failed, were analyzed and correlated with the overall survival (OS) from the date of first-line treatment failure. Results A total of 192 patients were included. Before the start of the first-line therapy, all patients had Child-Pugh class A liver reserves and Cancer of the Liver Italian Program (CLIP) scores ?4. After the failure of the first-line therapy, the median OS of the entire group was 4.0 months. Patients with Child-Pugh class A liver reserves, when the first-line treatment failed, had significantly better OS than patients with Child-Pugh class B or C liver reserves (median, A vs. B vs. C = 7.5 vs. 1.3 vs. 1.0 month, p <0.001). According to the key eligibility criteria of 3 published clinical trials for second-line therapy, 41%-56% of patients were potentially eligible. Compared to patients who were ineligible for clinical trials, potentially eligible patients had longer OS with a median of 7.8-8.6 months. Conclusions Patients with advanced HCC who failed first-line therapy could have substantially improved prognosis if they had Child-Pugh A liver reserves or were potentially eligible for clinical trials. | - |
dc.relation.ispartof | Journal of Hepatology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alpha fetoprotein; bevacizumab; brivanib; capecitabine; erlotinib; fluorouracil derivative; placebo; sorafenib; sunitinib; tamoxifen; thalidomide; tivantinib; UFT; adult; advanced cancer; article; cancer prognosis; cancer survival; Child Pugh score; correlation analysis; human; hyperbilirubinemia; liver cell carcinoma; middle aged; overall survival; phase 2 clinical trial (topic); phase 3 clinical trial (topic); priority journal; systemic therapy; Taiwan; treatment failure; Barcelona Clinic Liver Cancer; BCLC; Cancer of the Liver Italian Program; Clinical trials; CLIP; Eastern Cooperative Oncology Group performance status; ECOG PS; HCC; Hepatocellular carcinoma; hepatocellular carcinoma; National Taiwan University Hospital; NTUH; OS; overall survival; Prognosis; Second-line therapy; Survival; time to progression; TTP; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Prognosis; Taiwan; Treatment Failure; Treatment Outcome; Young Adult | - |
dc.title | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.jhep.2013.08.027 | - |
dc.identifier.pmid | 24036008 | - |
dc.identifier.scopus | 2-s2.0-84892538394 | - |
dc.relation.pages | 313-318 | - |
dc.relation.journalvolume | 60 | - |
dc.relation.journalissue | 2 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Radiology | - |
crisitem.author.dept | Medical Imaging-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0002-7498-4183 | - |
crisitem.author.orcid | 0000-0001-8975-9491 | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。